Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma A/S (ASND)
:ASND
ASND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$111.09 - $169.37
Previous CloseN/A
Volume129.18K
Average Volume (3M)523.70K
Market Cap
$10.05B
Enterprise Value$8.77B
Total Cash (Recent Filing)€559.54M
Total Debt (Recent Filing)€856.62M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 21, 2025EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.13
Shares Outstanding60,689,487
10 Day Avg. Volume435,913
30 Day Avg. Volume523,702
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$208.82Price Target Upside24.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Ascendis Pharma News
PremiumCompany Announcements
VISEN Pharmaceuticals Prices IPO on Hong Kong Stock Exchange
PremiumCompany Announcements
Ascendis Pharma Grants Employee Warrants to Strengthen Retention---
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst maintains a Buy rating with a price objective of $192, indicating confidence in the stock's potential.
Competitive AdvantageThe US Yorvipath launch began with Yorvipath’s first-to-market profile as a clear advantage over competitors.
Market LaunchYorvipath has been launching very well in hypoparathyroidism, with 908 prescriptions in the US.
Bears Say
Clinical Data ReliabilityThe Phase 3 study of eneboparatide met the primary endpoint but included no additional details, suggesting the 24-week data may not be fully reliable.
Competitive LandscapeThere are potential concerns regarding the competitive landscape due to the CALYPSO study data.
Conflict Of InterestThe analyst report contains a conflict of interest disclosure, which may affect the objectivity of the report.
---
Ownership Overview
―
Insiders
31.86% Mutual Funds
0.22% Other Institutional Investors
66.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $111.09 and its highest was $169.37 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $10.05B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is May 21, 2025 which is in 56 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on Feb 12, 2025. The company reported -$0.691 earnings per share for the quarter, beating the consensus estimate of -$1.06 by $0.368.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is -1.58.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 60,689,487 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of -$0.691 in its last earnings report, beating expectations of -$1.06. Following the earnings report the stock price went up 12.962%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
---
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$208.82 (24.31% Upside)
$208.82 (24.31% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 436.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.47%
12-Months-Change
Fundamentals
Return on Equity
357.68%
Trailing 12-Months
Asset Growth
33.92%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial growth and successful product launches, particularly with YORVIPATH in the U.S., and promising developments in the pipeline. However, challenges remain with revenue fluctuations for SKYTROFA and market penetration hurdles for YORVIPATH.Read More>---
ASND Stock 12 Month Forecast
Average Price Target
$208.82
▲(24.31% Upside)
Technical Analysis
Best Analysts Covering ASND
1 Year
1 Year Success Rate
24/29 ratings generated profit
1 Year Average Return
+27.71%
reiterated a buy rating 9 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 82.76% of your transactions generating a profit, with an average return of +27.71% per trade.
---